UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000005366 |
|---|---|
| Receipt number | R000006291 |
| Scientific Title | A phase II study of trastuzumab added to docetaxel and S-1 for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. |
| Date of disclosure of the study information | 2011/04/26 |
| Last modified on | 2018/01/04 09:50:45 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2011/04/01 21:15:07 | ||
| 2 | Update | 2011/04/19 16:22:54 | Public title Acronym |
|
| 3 | Update | 2011/04/19 16:24:04 | Acronym |
|
| 4 | Update | 2011/06/07 14:16:17 | Recruitment status |
|
| 5 | Update | 2012/10/01 11:29:46 | Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
| 6 | Update | 2013/10/01 20:35:52 | Email |
|
| 7 | Update | 2017/10/05 14:29:31 | Name of primary person or sponsor Organization Organization |
|
| 8 | Update | 2017/10/05 14:31:19 | Recruitment status Last follow-up date |
|
| 9 | Update | 2018/01/04 09:50:45 | Recruitment status Date analysis concluded Publication of results URL related to results and publications |
